Axon CEO Tops U.S. Executive Pay with $164.5 Million in 2024

Published 1 days agoAXON

Axon CEO Tops U.S. Executive Pay with $164.5 Million in 2024

Patrick W. Smith, CEO of Axon Enterprise, has been named the highest-paid executive in the U.S. for 2024, as shown in recent reports. Smith's total compensation package reached a staggering $164.5 million, a remarkable jump from just $40,058 in the previous year. This substantial increase highlights a major shift in executive compensation structures, with a focus on stock awards driving the numbers higher as cited by Investing.com.

The vast majority of Smith's payment, approximately 99.6%, came in the form of stock awards, with his base salary at a modest $31,201. These stock options are closely linked to the company’s performance, based on criteria such as revenue growth, adjusted EBITDA margin, new market bookings, and new product adoption, as noted by Panabee.com. Such incentive structures are common in industries that prioritize long-term growth and shareholder returns.

This leading compensation package reflects a broader industry trend, where executive pay is increasingly tied to company performance and shareholder value. Compared to his peers, Smith's pay far outpaces others like James Vena of Union Pacific, who earned $17.6 million. As Axon's stock continues to perform well, the alignment of compensation with company success stands as a key strategy for maintaining competitive leadership and incentivizing performance.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Raytheon Lands $1.1 Billion Missile Contract Boost

Raytheon Lands $1.1 Billion Missile Contract Boost

8 minutes agoRTX

Raytheon Technologies, a key player in aerospace and defense, secured a significant $1.1 billion contract modification from the U.S. Department of Defense. This contract focuses on enhancing air-to-air combat capabilities through the production of additional Advanced Medium Range Air-to-Air Missiles (AMRAAM), along with supportive systems and engineering activities. Support for foreign military sales is a major component of this contract, with approximately $603 million coming from allied nations including Bahrain, Bulgaria, Canada, and others. The expanded production is geared towards these international partners, emphasizing the global reliance on the AMRAAM system. Reuters detailed that work is projected to conclude by the end of 2028. This new contract adds to a prior $1.15 billion agreement in 2023, underlining Raytheon's ongoing commitment to supplying cutting-edge missile technology. The versatile AMRAAM, used by 36 countries, continues to be a cornerstone of modern air defense, adaptable to a range of combat aircraft including the F-15 and F-35. This development signifies Raytheon's active role in bolstering both U.S. and allied defense strategies.

Jacobs Pursues Space Force Contract Amid Stock Variations

Jacobs Pursues Space Force Contract Amid Stock Variations

22 minutes agoJ

As of June 2025, no official announcements have confirmed that Jacobs Technology has secured a $4 billion contract with the U.S. Space Force. The most recent significant deal for Jacobs was a February 2023 contract valued at $3.2 billion for operations at NASA's Kennedy Space Center. Meanwhile, Jacobs had historically managed to secure a $4.6 billion contract for missile defense services back in 2017, according to UPI. Jacobs is not new to the defense sector, with a track record of winning substantial contracts. In May 2023, the company joined forces with NORAD and the U.S. Space Force to enhance digital operations, as reported by Jacobs. However, no specific financial details of this partnership have been unveiled, keeping the financial community speculative about Jacobs' standing in the competitive defense contracting sector. Despite the lack of a confirmed Space Force deal, Jacobs Solutions Inc remains in focus on the stock market. As of the latest trading session, Jacobs' stock price stood at $124.13, marking a slight decrease of 0.02% from the previous close. The session opened at $125.72 with an intraday high of $126.31 and a low of $123.55. These fluctuations highlight the market's cautious watch on Jacobs’ potential future developments.

Merck in Talks to Acquire MoonLake Immunotherapeutics for Over $3 Billion

Merck in Talks to Acquire MoonLake Immunotherapeutics for Over $3 Billion

37 minutes agoMRK

Merck is currently in discussions to purchase the Swiss biotech company MoonLake Immunotherapeutics. The pharmaceutical giant made a nonbinding offer that surpasses MoonLake's market valuation of $2.6 billion. However, this initial bid was rejected, according to the Financial Times. Despite MoonLake's refusal of the offer, negotiations might still be alive, as there is a possibility of interest from other potential buyers. MoonLake has a promising developmental pipeline, with its lead drug, sonelokimab, in phase-three trials aimed at treating hidradenitis suppurativa and psoriatic arthritis. This acquisition attempt marks Merck's return to significant biotech deals, following its acquisition of EyeBio last year. The interest in MoonLake occurs amidst a backdrop of slowed healthcare mergers and acquisitions due to broader economic uncertainties and regulatory challenges, although successful deals continue to emerge.

FDA Greenlights Expanded Access for ImmunityBio's ANKTIVA

FDA Greenlights Expanded Access for ImmunityBio's ANKTIVA

52 minutes agoIBRX

ImmunityBio has received authorization from the U.S. Food and Drug Administration (FDA) for an Expanded Access Protocol (EAP) to provide its drug ANKTIVA® (N-803) to patients suffering from lymphopenia. This condition, marked by a reduction in lymphocyte levels, frequently affects individuals undergoing treatments like chemotherapy and radiation. By gaining EAP status, ImmunityBio can offer ANKTIVA as a potential treatment opportunity for such patients needing immediate medical intervention. Prior to this, ImmunityBio's efforts had been bolstered by its receipt of the Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA, as well as for CAR-NK (PD-L1 t-haNK). This designation covers the drug's use not only for lymphopenia but also for multiply relapsed locally advanced or metastatic pancreatic cancer, a further affirmation of ANKTIVA’s therapeutic promise. Reuters previously reported that clinical data underscored ANKTIVA's capability to effectively engage NK cells, CD4+ T cells, CD8+ T cells, and memory T cells while not increasing the count of suppressive T regulatory cells. According to ImmunityBio, ANKTIVA is expected to hit the United States market by mid-May 2024, marking a significant step forward in broadening available treatment options for patients faced with the challenges of lymphopenia, especially in the backdrop of standard cancer therapies. These developments reflect the biotech company's ongoing commitments to advancing novel treatments and expanding therapeutic access.